Ligelizumab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AllergyUrticariaChronic Spontaneous UrticariaFood Allergy

149 competitors in Allergy

#DrugCompanyPhaseTrials

1

Flovent

GSK

Phase 3

12

Clarinex

OOrganon and Co

Phase 3

13

REGN5715

Regeneron

Phase 3

14

REGN5713

Regeneron

Phase 3

15

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

36

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

17

Ligelizumab

Novartis

Phase 3

18

DUPIXENT

Regeneron

Phase 2

—9

Allergy Immunotherapy (AIT)

AALK-Abelló A/S

Phase 3

110

Etokimab

AAnaptysBio, Inc.

Phase 2

1Show 19 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Spontaneous Urticaria3 trials

Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)

Completed·Novartis·Phase 2·NCT03437278·49 enrolled

A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients

Completed·Novartis·Phase 2·NCT02649218·226 enrolled

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Terminated·Novartis·Phase 3·NCT04210843·1,033 enrolled

Urticaria2 trials

Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria

Terminated·Novartis·Phase 1·NCT04513548·11 enrolled

Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Terminated·Novartis·Phase 3·NCT05024058·39 enrolled

Safety and Efficacy2 trials

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Completed·Novartis·Phase 3·NCT03907878·66 enrolled

A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Completed·Novartis·Phase 3·NCT03580369·1,072 enrolled

Adolescent1 trial

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

Completed·Novartis·Phase 3·NCT03580356·1,078 enrolled

Food Allergy1 trial

Long-term Extension Study of Ligelizumab in Food Allergy

Terminated·Novartis·Phase 3·NCT05678959·163 enrolled

2 more indications

Aged1 trial

Global Managed Access Program Cohort for Ligelizumab in CSU

No longer available·Novartis··NCT04903613

Allergy1 trial

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Terminated·Novartis·Phase 3·NCT04984876·211 enrolled

Details

Drug Info

Related News